INTS Intensity Therapeutics, Inc.
Stock Price & Overview

$1.30-0.61 (-31.94%)4:00 PM 04/23/25
NASDAQ | $USD | Post-Market: $1.30 7:59 PM

INTS Stock Price

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close
Expand For Key Data »

Quant Ranking

INTS Analysis

INTS News

See All News »

Latest Headlines

Ratings Summary

People Also Follow

Similar to INTS

ETFs Holding INTS

INTS Company Profile

Intensity Therapeutics, Inc. logo
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Sector
Health Care
Industry
Biotechnology
Employees
6
Founded
2012
Address
  • 1 Enterprise Drive
  • Suite 430
  • Shelton, CT, 06484-4779
  • United States
Phone Number
203 221 7381
Website
www.intensitytherapeutics.com
Hide

INTS Revenue

More On Revenue »

INTS Earnings Per Share

More On Earnings »

Earnings Estimates

Earnings Revisions

Valuation

Profitability

Momentum

Capital Structure

Dividends

INTS does not currently pay a dividend.

INTS Ownership

INTS Peers

Risk

Technicals

INTS SEC Filings

See All SEC Filings »

Press Releases

See All Press Releases »

INTS Income Statement

INTS Balance Sheet

INTS Cash Flow Statement

INTS Long Term Solvency

Discover More

You may be interested in:

Intensity Therapeutics, Inc. (INTS) Frequently Asked Questions